Lara Krupka-Longpre
Corporate Officer/Principal at MIRUM PHARMACEUTICALS, INC.
Net worth: 3 M $ as of 30/03/2024
Profile
Lara Krupka-Longpre is currently the Chief Development Officer at Mirum Pharmaceuticals, Inc. She previously worked as the Chief Operating Officer at MedGenesis Therapeutix, Inc. and SillaJen Biotherapeutics, Inc. Additionally, she held the position of Vice President-Proposals & Contracts at PRA Health Sciences, Inc. Krupka-Longpre holds an MBA from Queen's University, an undergraduate degree from Cornell University, and a graduate degree from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/02/2024 | 104,407 ( 0.22% ) | 3 M $ | 30/03/2024 |
Lara Krupka-Longpre active positions
| Companies | Position | Start |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 30/11/2018 |
Former positions of Lara Krupka-Longpre
| Companies | Position | End |
|---|---|---|
MedGenesis Therapeutix, Inc.
 MedGenesis Therapeutix, Inc. Medical SpecialtiesHealth Technology MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation. | Chief Operating Officer | 31/05/2018 |
| PRA HEALTH SCIENCES, INC. | Corporate Officer/Principal | - |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Chief Operating Officer | - |
Training of Lara Krupka-Longpre
| Queen's University | Masters Business Admin |
| Cornell University | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MIRUM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
PRA Health Sciences, Inc.
 PRA Health Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services. The Data Solutions segment involves in data and analytics; technology solutions and real-world insights, and services primarily to the company's life science clients. The company was founded in 1976 and is headquartered in Raleigh, NC. | Commercial Services |
MedGenesis Therapeutix, Inc.
MedGenesis Therapeutix, Inc. Medical SpecialtiesHealth Technology MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation. | Health Technology |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
- Stock Market
- Insiders
- Lara Krupka-Longpre
